MicroTech Medical (Hangzhou) Co

MicroTech Medical (Hangzhou) Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of MicroTech Medical (Hangzhou) Co (2235.HK) as of Oct 29, 2026 is -133.66. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -2.77 — a change of 4,730.42% (lower).

EV/FCF

-133.66

YoY

4,730.42%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of MicroTech Medical (Hangzhou) Co is 2025 -133.66 . EV/FCF (Enterprise Value to Free Cash Flow) of MicroTech Medical (Hangzhou) Co was 2024 -2.77 . It decreases by 4,730.42% lower compared to the previous year.

The MicroTech Medical (Hangzhou) Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-43.64 CNY
Jan 1, 2020
-45.85 CNY
Jan 1, 2021
-1.92 CNY
Jan 1, 2022
-1.64 CNY
Jan 1, 2023
-2.10 CNY
Jan 1, 2024
-2.77 CNY
Jan 1, 2025
-133.66 CNY
The MicroTech Medical (Hangzhou) Co EV/FCF history
YEAREV/FCFYoY
-133.66+4,730.42%
-2.77+31.96%
-2.10+27.79%
-1.64-14.47%
-1.92-95.82%
-45.85+5.07%
-43.64—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MicroTech Medical (Hangzhou) Co Stock analysis

What does MicroTech Medical (Hangzhou) Co do? MicroTech Medical (Hangzhou) Co., Ltd. generates revenue through the sale of diabetes management medical devices and consumables, including the Equil applicator insulin pump system, blood glucose monitoring systems, and the AiDEX G7 continuous blood glucose monitoring system. These products are commercialized for overseas markets such as the United States and the European Union, targeting healthcare providers and patients seeking advanced diabetes care solutions. The company's R&D efforts focus on developing products like the artificial pancreas, which remains in the research phase but is expected to contribute to future revenue streams. The firm's primary customers are healthcare institutions and end-users in international markets, with a strong emphasis on the United States and European Union regions. By leveraging its established product portfolio, MicroTech Medical capitalizes on the growing demand for innovative diabetes management solutions, ensuring consistent revenue from both existing and emerging product lines. The company's IPO in 2021 provided additional capital to support further development and market expansion. MicroTech Medical (Hangzhou) Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MicroTech Medical (Hangzhou) Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of MicroTech Medical (Hangzhou) Co is -133.66 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of MicroTech Medical (Hangzhou) Co changed from -2.77 to -133.66, representing a 4,730.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) MicroTech Medical (Hangzhou) Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s MicroTech Medical (Hangzhou) Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — MicroTech Medical (Hangzhou) Co

All Key Metrics — MicroTech Medical (Hangzhou) Co